Clinically, the combination of anti–PD-L1 atezolizumab with anti-VEGF bevacizumab has already shown that modulating the microenvironment (by normalizing vasculature and reducing myeloid suppression via VEGF blockade) can raise the effectiveness of T-cell checkpoint therapy in HCC [1]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.